Autonomix Medical (AMIX) to Release Earnings on Wednesday

Autonomix Medical (NASDAQ:AMIX) is expected to announce its Q1 2027 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($6.4050) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Autonomix Medical Trading Up 434.2%

Shares of AMIX stock opened at $19.50 on Wednesday. The stock has a 50 day simple moving average of $6.68 and a 200-day simple moving average of $7.76. The company has a market cap of $10.53 million, a price-to-earnings ratio of -0.26 and a beta of -1.17. Autonomix Medical has a 12-month low of $2.44 and a 12-month high of $32.55.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on AMIX shares. Weiss Ratings raised Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Zacks Research raised Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $42.00.

Autonomix Medical News Summary

Here are the key news stories impacting Autonomix Medical this week:

• Positive Sentiment: Autonomix Medical received a broad new U.S. patent expanding protection for its precision neuromodulation platform. The technology is designed to sense and map nerves, then selectively target them for treating tumors and cancer-related pain. The patent could strengthen the company’s competitive position and support future commercialization, which appears to be the main catalyst for the stock’s move higher. Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
• Positive Sentiment: The patent’s coverage of nerve sensing, mapping and targeted therapy may increase the potential value of Autonomix’s platform, particularly if the company can translate the intellectual property into clinical, partnership or licensing opportunities. Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion
• Neutral Sentiment: AMIX trading was halted repeatedly under Nasdaq’s Limit Up-Limit Down (LULD) mechanism. These pauses reflect sharp price movements and elevated volatility, helping explain the stock’s dramatic intraday behavior but providing no direct information about operations or valuation.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.